Please ensure Javascript is enabled for purposes of website accessibility

2 Great Stocks You Can Buy on Sale

By George Budwell - Updated Oct 3, 2019 at 5:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie and Amgen are two great stocks that are way too cheap right now.

The stock market's recent volatility shouldn't concern investors with a long-term outlook. In fact, it's probably a blessing in disguise for the buy-and-hold crowd. Several great stocks, after all, are now trading at attractive valuations. 

In the beaten-up healthcare sector, for instance, AbbVie (ABBV -0.22%) and Amgen (AMGN 1.08%) stand out as two outstanding buys following their poor showing through the first nine months of 2019. Here's why these top dividend-paying biotech stocks are worth adding to your portfolio right now.

A businessman standing in a small boat looking off into the distance.

Image source: Getty Images.

AbbVie: Buy the fear

AbbVie's shares are shrouded in fear right now. The singular reason is that the company's main revenue source -- the anti-inflammatory drug Humira -- has firmly entered the back end of its rather remarkable run as one of the industry's most profitable products.

Emphasizing this point, Humira's sales appear to have crested at around $20 billion in 2018, with biosimilars taking a heavy toll in Europe this year. Some Wall Street analysts have even floated the idea that Humira's sales might plummet by an eye-popping 85% from their former high-water mark by 2025. That's obviously not a favorable trend line, but it's also not the end of the world. 

AbbVie has built out a solid portfolio of next-generation products and it recently inked a merger agreement with Allergan (AGN) that will immediately soften the blow from Humira's demise. Underscoring this point, AbbVie should have no fewer than six blockbuster products (Botox, Imbruvica, Orilissa, Rinvoq, Skyrizi, and Venclexta) by 2025, thanks to its top-notch clinical pipeline and tie-up with Allergan.  

Apart from AbbVie's impressive portfolio of newer growth products, there are two more compelling reasons to consider buying this elite biotech stock soon. First, AbbVie's shares are dirt cheap right now at 7.56 times forward earnings. Second, this Dividend Aristocrat sports a substantial yield of 5.84% at current levels. Bargain-hunters, in kind, should probably take advantage of AbbVie's yearlong downturn. This top drugmaker will eventually rebound after all. 

Amgen: Better days are ahead

Amgen's shares have fallen by nearly 3% so far this year. As a result, the stock is now trading at 12 times forward earnings, which is a lower-tier valuation for a blue chip biotech -- especially one that sports a slightly above-average dividend yield of 3%. Still, the market appears more than content to simply sit on the sidelines when it comes to this top dividend stock, despite its attractive valuation and juicy dividend.

What's keeping investors at bay? Amgen is going through a radical makeover right now, and the final product remains a work in progress, to put it mildly. The brief rundown is that newer growth products like the migraine treatment Aimovig and cholesterol-lowering drug Repatha haven't been able to fully offset the declines emanating from the biotech's portfolio of aging superstars. Amgen's top line, in fact, is forecast to dip by 3.9% in 2019. 

Another area of concern is the biotech's oncology portfolio. Some of the company's most important early-stage cancer assets simply haven't lived up to expectations in the clinic. These setbacks have weighed on Amgen's shares this year, which makes sense given their importance to the biotech's long-term value proposition.

Still, there are two solid reasons to consider buying this blue chip biotech stock right now. First up, Amgen's recent acquisition of the anti-inflammatory medicine Otezla is expected to immediately boost earnings and quarterly sales. The company should, in fact, return to top-line growth by next year. Second, Amgen has one of the largest cash positions within the entire space. So there's a good chance that the biotech will pursue more bolt-on acquisitions in order to accelerate its return to form. 

The bottom line is that Amgen definitely has the pieces in place to move past these various headwinds. Now, this turnaround may not materialize overnight, but it will almost certainly happen. As such, patient investors may want to dig into this story before the market starts to change its tune.

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$251.08 (1.08%) $2.69
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$142.29 (-0.22%) $0.31
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.